文献速递临床试验与 GCP真实世界研究与卫生经济

T-SHARP项目:针对注射吸毒HIV感染者减害远程干预的多中心随机对照试验研究方案

Project T-SHARP: study protocol for a multi-site randomized controlled trial of tele-harm reduction for people with HIV who inject drugs.
PubMed 文献 · Trials · 2023-02-07

T-SHARP是一项开放标签、多中心、随机对照优效性试验,计划从佛罗里达州迈阿密、劳德代尔堡和坦帕的针具服务项目招募240名HIV未控制(HIV RNA>200)的注射吸毒者,随机分配至减害远程干预组或异地HIV照护链接组,主要比较两组在3、6、12个月随访期间HIV病毒抑制(HIV RNA<200拷贝/ml)的时间平均效应。

要点

  • T-SHARP试验在针具服务项目场所内提供减害远程干预,并与异地HIV照护链接进行比较。
  • 主要结局为3、6、12个月随访期间时间平均HIV病毒抑制(HIV RNA<200拷贝/ml)。
  • 次要结局包括通过尿药筛测量的MOUD启动和HCV治愈(治疗完成后12周HCV RNA阴性)。

核心结论

  • T-SHARP试验将是首个在注射吸毒HIV未控制人群中测试通过针具服务项目提供的减害远程干预以支持HIV病毒抑制的疗效的试验。
  • 该试验旨在改变注射吸毒者获取HIV照护的方式并改善HIV临床结局。

研究设计与样本

  • 开放标签、多中心、随机对照优效性试验,两个平行治疗组。
  • 计划从佛罗里达州迈阿密、劳德代尔堡和坦帕的针具服务项目招募240名HIV未控制(HIV RNA>200)的注射吸毒者。
  • 参与者随机分配至减害远程干预组或异地HIV照护链接组。

主要发现

  • 主要目标为比较减害远程干预组在针具服务项目启动ART与异地HIV诊所照护链接组在随访期间病毒抑制的疗效。
  • HIV RNA<200拷贝/ml视为病毒抑制。
  • 主要试验结局为3、6、12个月随访期间时间平均HIV病毒抑制(HIV RNA<200拷贝/ml)。
  • 次要结局包括通过尿药筛测量的MOUD启动和HCV治愈(治疗完成后12周HCV RNA阴性)。
  • 将进行成本效果分析。

临床怎么用

  • 减害远程干预由同伴进一步支持以促进依从性并弥合数字鸿沟。
  • 该创新翻转医疗模式搁置传统医疗系统,减少多层次照护障碍,并在注射吸毒者所在之处提供服务。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The resurgence of HIV outbreaks and rising prevalence among people who inject drugs (PWID) remain exigent obstacles to Ending the HIV Epidemic in the USA. Adapting a low threshold, comprehensive treatment model for PWID with HIV can leverage syringe services programs (SSPs) to increase availability and accessibility of antiretrovirals (ART), medications for opioid use disorder (MOUD), and hepatitis C cure. We developed Tele-Harm Reduction, a telehealth-enhanced, harm reduction intervention delivered within an SSP venue. METHODS: The T-SHARP trial is an open-label, multi-site, randomized controlled superiority trial with two parallel treatment arms. Participants (n=240) recruited from SSPs in Miami, Ft. Lauderdale, and Tampa, Florida, who are PWID with uncontrolled HIV (i.e., HIV RNA>200) will be randomized to Tele-Harm Reduction or off-site linkage to HIV care. The primary objective is to compare the efficacy of Tele-Harm Reduction for initiation of ART at SSPs vs. off-site linkage to an HIV clinic with respect to viral suppression across follow-up (suppression at 3, 6, and 12 months post randomization). Participants with HIV RNA<200 copies/ml will be considered virally suppressed. The primary trial outcome is time-averaged HIV viral suppression (HIV RNA <200 copies/ml) over 3-, 6-, and 12-month follow-up. Secondary outcomes include initiation of MOUD measured by urine drug screen and HCV cure, defined as achieving 12-week sustained virologic response (negative HCV RNA at 12 weeks post treatment completion). A cost-effectiveness analysis will be performed. DISCUSSION: The T-SHARP Trial will be the first to our knowledge to test the efficacy of an innovative telehealth intervention with PWID with uncontrolled HIV delivered via an SSP to support HIV viral suppression. Tele-Harm Reduction is further facilitated by a peer to support adherence and bridge the digital divide. This innovative, flipped healthcare model sets aside the traditional healthcare system, reduces multi-level barriers to care, and meets PWID where they are. The T-SHARP trial is a pragmatic clinical trial that seeks to transform the way that PWID access HIV care and improve HIV clinical outcomes. TRIAL REGISTRATION: ClinicalTrials.gov NCT05208697. Trial registry name: Tele-Harm Reduction. Registration date: January 26, 2022.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Tookes HE, Oxner A, Serota DP, et al. Project T-SHARP: study protocol for a multi-site randomized controlled trial of tele-harm reduction for people with HIV who inject drugs. Trials. 2023. PMID: 36750867. doi:10.1186/s13063-023-07074-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。